ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: osteoporosis

Fracture & an Aging World

Jason Liebowitz, MD, FACR  |  September 24, 2024

Insights into osteoporosis treatments as societies around the world age.

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:APLARAPLAR 2024Asia Pacific League of Associations for Rheumatology (APLAR)bisphosphonatesdenosumabdrug holidayOsteoporosisosteoporosis treatmentsromosozumabzoledronic acid

An Expert’s Take on the Best Research in RA to Be Presented at ACR Convergence 2024

Keri Losavio  |  September 19, 2024

With thousands of research abstracts and posters being presented at ACR Convergence 2024, Nov. 14–19, at the Walter E. Washington Convention Center in Washington, D.C., figuring out which research is important today, which could prove important in the future, what has the potential to affect clinical care or prove the basis for future research is…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

The Rheumatologist’s Role in Sarcoidosis

Samantha C. Shapiro, MD  |  August 26, 2024

Rheumatologists are uniquely positioned to care for patients with sarcoidosis. Here are insights into the condition, its treatment and more.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsOther Rheumatic Conditions Tagged with:EULAREULAR 2024

What’s New in Polymyalgia Rheumatica?

Jason Liebowitz, MD, FACR  |  July 31, 2024

Should all patients with polymyalgia rheumatica (PMR) have a vascular ultrasound assessment? What treatments are the safest and most efficacious for patients with PMR? Frank Buttgereit, MD, answered these questions and highlighted the latest research on PMR in this session at EULAR 2024.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPain Syndromes Tagged with:EULAR 2024GCAgiant cell arteritis (GCA)PMRPolymyalgia Rheumatica

The Ins & Outs of Private Rheumatology Practice

Vanessa Caceres  |  July 29, 2024

For a podcast audience, Dr. Sunil Abraham shared pearls for evaluating what setting best fits you and your lifestyle, and what a career in community practice means.

Filed under:Career DevelopmentOpinionPractice SupportProfessional Topics Tagged with:ACR on AirCareerCareer developmentcommunity practicePrivate practicework-life balance

Ethics Forum: The Current Landscape of Artificial Intelligence in Medicine

Jeanne Gosselin, MD  |  May 6, 2024

A handful of articles on artificial intelligence (AI) have graced the pages of this publication in the past six years, including one by Bharat Kumar, MD, in November 2022. Dr. Kumar highlighted the exciting potential of AI in rheumatology, including machine learning (ML) algorithms for the prediction of response to methotrexate and a predictive model…

Filed under:EthicsPractice SupportTechnology Tagged with:artificial intelligenceDiagnosisEthics Forum

Biosimilars to Denosumab Approved with an Interchangeable Designation

Michele B. Kaufman, PharmD, BCGP  |  April 18, 2024

The FDA has approved the first interchangeable biosimilars for denosumab.

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabdenosumab-bbdzJubbontiProliaWyostXgeva

HR & Other Aspects of Private Practice: A Conversation with Tien-I Karleen Su, MD, FACR

Vanessa Caceres  |  March 22, 2024

Despite challenges, private practice has many rewards, such as more autonomy, says Tien-I Karleen Su, MD, FACR, chair of the ACR’s Community Practice Council.

Filed under:Practice SupportProfiles Tagged with:Community Practice CouncilPrivate practice

Focus on Community Practice Rheumatology

Vanessa Caceres  |  March 14, 2024

Community practice rheumatology brings with it certain challenges, but it also offers rewards, such as autonomy and the capacity to develop deep relationships with patients. Three rheumatologists discuss the challenges and rewards of private practice.

Filed under:American College of RheumatologyOpinionPractice Support

FDA Issues Boxed Warning for Denosumab & Approves a Generic NSAID

Michele B. Kaufman, PharmD, BCGP  |  February 27, 2024

In January, the U.S. Food & Drug Administration approved indomethacin in an oral suspension, a generic version of Indocin Oral Suspension. The agency also issued a boxed warning and updated label for denosumab, warning of the risks of severe hypocalcemia in patients with chronic kidney disease.

Filed under:AnalgesicsBiologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabDrug SafetyFDA approvalOsteoporosisU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 59
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences